Background—This study was designed to determine whether (1) P2Y12 antagonism
synergizes with other antithrombotics and (2) anticoagulants (thrombin inhibitors) affect the …

The critical role for ADP in arterial thrombogenesis was established by the clinical success
of P2Y12 antagonists, currently used at doses that block 40–50% of the P2Y12 on platelets …

P2Y 12 antagonism is a key therapeutic strategy in the management and prevention of
arterial thrombosis. The objective of this study was to characterize the pharmacodynamic …

Essentials• In acute coronary syndromes, dual antiplatelet therapy inhibits platelets but
confers a bleeding risk.• Healthy male volunteers received clopidogrel or ticagrelor plus …

INTRODUCTION: With the arrival of the potent P2Y12 antagonists, ticagrelor and prasugrel,
the need for co-treatment with aspirin in acute coronary syndromes must be re-examined …

ABSTRACT MRS‐2179 is a selective P2Y1 receptor antagonist, a strong inhibitor of ADP‐
induced platelet aggregation in vitro and ex vivo. By iv administration to mice MRS‐2179 …

Previous studies in experimental models revealed a role for the P2Y 1 platelet ADP receptor
in systemic vascular thromboembolism models. In the present work, we used models of …

Background: In our previous in vitro study, we reported a constitutively active chimeric P2Y
12 (cP2Y 12) and found that AR‐C78511 is a potent inverse agonist at this receptor. The …

Background: Aspirin and antagonists of platelet ADP P2Y 12 receptors are often
coprescribed for protection against thrombotic events. However, blockade of platelet P2Y 12 …

Adenosine diphosphate directly induces platelet aggregation via the G-protein coupled P2Y
1 and P2Y 12 receptors. P2Y 12, but not P2Y 1, receptor antagonists are available in the …